Company Filing History:
Years Active: 2014-2024
Title: Innovator Phillippe Duchateau: Pioneering Advances in Immunotherapy
Introduction
Phillippe Duchateau is a notable inventor based in Cerny, France. He has made significant contributions to the field of immunotherapy, particularly through his innovative patents. With a total of 3 patents, Duchateau is recognized for his work in engineering immune cells to target cancer effectively.
Latest Patents
Duchateau's latest patents include groundbreaking inventions that enhance the capabilities of immune cells. One of his notable patents is the "Universal anti-CD22 chimeric antigen receptor engineered immune cells." This invention relates to engineered immune cells endowed with CD22 Chimeric Antigen Receptors (CD22 CAR) that have a deletion in the TRAC gene. These cells are designed to redirect immune specificity and reactivity toward selected tumor cells, making them particularly effective for treating relapsed refractory CD22 expressing cancers. Another significant patent is the "Use of meganucleases for inducing homologous recombination ex vivo and in toto in vertebrate somatic tissues and application thereof." This patent focuses on the use of meganucleases for cleaving DNA in non-human or isolated human cells, facilitating genome engineering and gene therapy applications.
Career Highlights
Duchateau is currently associated with Cellectis S.A., a company that specializes in developing innovative therapies based on gene editing technologies. His work at Cellectis has positioned him as a leader in the field of immunotherapy, contributing to advancements that have the potential to transform cancer treatment.
Collaborations
Throughout his career, Duchateau has collaborated with esteemed colleagues such as Sylvain Arnould and Patrick Chames. These collaborations have fostered an environment of innovation and have led to significant advancements in the field of immunotherapy.
Conclusion
Phillippe Duchateau's contributions to immunotherapy through his patents and work at Cellectis S.A. highlight his role as a pioneering inventor in the field. His innovative approaches to engineering immune cells are paving the way for new cancer treatments.